Sequence Analysis Clinical Trial
Official title:
Analysis of Tumor Mutations and Tumor Microenvironment Using Archival Paraffin-embedded Tumor Specimens
Genomic alterations have long been recognized as an important factor in tumor formation and
drive tumor cell growth. However, the degree of genomic mutation (tumor mutation load, TMB)
varies widely between tumors. In addition to gene mutations in tumor cells, the extent of
immune cell infiltration in tumor tissues and the type and nature of immune cells (tumor
microenvironment, TME) also play an important role in controlling tumor growth.
In recent years, more and more clinical studies have shown that the degree of genomic
alteration (TMB) and tumor microenvironment (TME) have great potential in predicting a cancer
patients' response to immunotherapy. Therefore, understanding the interaction and correlation
between genomic alteration and tumor immune environment will not only deepen our
understanding of tumor biology but also provide an important reference for developing
immunotherapy treatment strategies for solid tumors.
This is a non-interventional, mono-centric retrospective study to be carried out in Chi Mei
Medical Center (CMMC) in order to determine the association between the genomic alterations
and gene expression level of immune-related genes in cancer. Samples in paraffin-embedded
block of biopsies or surgical pieces (either primary tumor or metastases) will be analyzed.
For each sample, clinically relevant data associated with treated cancer and needed for
characterization of tumor microenvironment will be documented. No additional procedures
besides those already used in the routine clinical practice will be applied to the patients.
Treatment assignment will be done according to the current practice.
This trial is, through accessing to archival tumor materials, to establish the relationship
between tumor mutation burden and tumor immune microenvironment for future immunotherapy
strategy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02813590 -
Ascitic Fluid Microbiome in Liver Cirrhosis
|